TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: sensitivity assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prolonged Smoking Abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: performance of Ambu® aScope™ 4 Cysto and aView™ Urologia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in alarm rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood Test Performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Sensory profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first painless contraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of whole exome sequencing in detecting causative mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bile Leak Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Depressive relapse (change in diagnostic status, SCID-I)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in depressive symptoms (MADRS-S)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biobehavioral Fibromyalgia Index
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Proportion of survived patients at 16 weeks
Endpoint domain: Mortality/survival
Primary endpoint: Difference in HKA angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Connor-Davidson Resilience Scale (CD-RISC)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Tumor Immune Infiltrates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Effective rate of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Raw walking distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Predictive identification of bacteria, genes, and proteins for UTI development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in SNOT-20 Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Fetal Heart Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Total Fetal Movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: 2-h post-OGTT glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: COPD Assessment Test score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Tumour resection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: neurological events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: any death
Endpoint domain: Mortality/survival
Primary endpoint: Change on Motor Function assessed by Wolf Motor Function scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change on Motor Function assessed by Fugl Meyer scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Achieving Abstinence From Cocaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of XL999
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum tolerated dose of XL999
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of mTORC1 and mTORC2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of days hospitalized for heart failure
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Prevalence of NASH with advanced fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Pharmacokinetics of darifenacin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants achieving a histologic treatment effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diffusing capacity for nitric oxide (DLNO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Lipoxin A4 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of appendix characterization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biliary stricture resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of hyperintensities and white matter lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reactive Hyperemia Index (RHI) and Augmentation Index (AI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Initial BCG complete response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Taste
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of self-perceived quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Frequency of relapses
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Reduced duration of relapses
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number and Percentage of Patients Who Experienced Adverse Events of Special Interest (AESI)
Endpoint domain: Adverse events/effects
Primary endpoint: leukemia relapse rate
Endpoint domain: Mortality/survival
Primary endpoint: safety and efficacy of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patterns of recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Change From Baseline in Glycated Hemoglobin A1c (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sunscreen application behavior
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in intensity of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in neurological status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: diagnostic accuracy of delirium detection tools
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute change in Thyroid nodule volume (TNV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Patient Enablement Index
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of patients free from complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amplitude of EMG signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of separate sensory percepts evoked
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hematoma thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Baseline MAD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of EXPAREL concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Pain Over the Last 24 Hours Score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Small airway function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of seizures recorded
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Concentration of postoperative maximum cardiac troponin T
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Household income
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Household food security
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pregnancy Rate Determined by Pearl Index
Endpoint domain: Mortality/survival
Primary endpoint: Pregnancy Rate Determined by Table of Life Analysis
Endpoint domain: Mortality/survival
Primary endpoint: Perineal wound healing rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Score on the Observational Scale of Behavioral Distress Revised (OSBD-R)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: HRV-Sympathetic-Short Measurement-LF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Mother-Child Dyads Who Complete Assessments & Biological Samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Telomere Length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Advanced Glycation End Products (AGEs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Small bowel water response to feeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Time to first documented recurrence of sustained VT/VF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Serious Adverse Event Frequency
Endpoint domain: Adverse events/effects
Primary endpoint: Neurocognitive Performance: Global Deficit Score (GDS), Week 24 Visit Score Minus Baseline Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Area Under the Concentration-time Curve (AUC) From Time Zero to 28 Days [AUC(0-28 Days)]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pituitary deficiencies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change From Baseline in T-cell Response to the VZV Vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CD4+/CD8+ Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: High T Regulatory Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of CGM values in target range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Verbal multidimensional scoring system for assessment of dysmenorrhea severity
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Percentage of Participants Achieving the Serotype-specific Pneumococcal IgG Antibody Threshold Value of ≥0.35 µg/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants Who Experience at Least 1 Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Device sensitivity/specificity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of communication styles employed
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Mean 24-hour Systolic Blood Pressure (SBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Cognition Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Quality of Life (QOL) Scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Accuracy rate of lymph node dissection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: False positive rate of lymph node dissection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: False negative rate of lymph node dissection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and specificity of lymph node dissection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change From Baseline to Week 4 in Systolic and Diastolic Blood Pressure (BP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean Change From Baseline to Week 4 in Heart Rate (HR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Presence of Botulinum Toxin Type A (BTX-A) Neutralising Putative Antibodies (NAbs) Following Injection of Dysport®
Endpoint domain: Adverse events/effects
Primary endpoint: Laparoscopic conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Bone destruction markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease specific survival (DSS)
Endpoint domain: Mortality/survival
Primary endpoint: Efficacy of heated air in killing head lice and their eggs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: successful outcome of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body representations
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Carotid intima-media thickness (cIMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Restenosis/reintervention after 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Improvement of safety in the treatment protocol
Endpoint domain: Adverse events/effects
Primary endpoint: Digestive damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Therapy drop-out rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of therapy sessions attended
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Acceptability of Intervention Measure (AIM)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Feasibility of Intervention Measure (FIM)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Intervention Appropriateness Measure (IAM)
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Improvement of airway stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Improvement of partial pressure of arterial oxygen (PaO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Retinal Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: rate of active CMV infection
Endpoint domain: Adverse events/effects
Primary endpoint: Mini International Neuropsychiatric Interview score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: post-operative quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Monthly dose-rate adherence percentage
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Adverse Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Change of Protective Qi Score (PQS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Protective Qi (PQi) Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in disease activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Myocardial triglyceride content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of tourniquet-induced hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of maximal VO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physician's Global Assessment (PGA) Rating
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Narcotrend index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Between-day reliability of kinematic parameters (MAX and ROM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Short-Form McGill Pain Questionnaire (MPQ) Pain Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 10-point Numeric Pain Intensity Rating Scale (NRS) pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Buccal Plate Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Buccal Soft Tissue Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Buccal Bone Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anthropometric Change in Abdominal Fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Anthropometric Change in Hip Circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Compliance to Breast Self Examination
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change from baseline in OA pain in the target knee
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence or absence of hallucination
Endpoint domain: Adverse events/effects
Primary endpoint: Adult Assisting Hand Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Life Balance Inventory
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Progression-free survival (PFS) in all patients
Endpoint domain: Mortality/survival
Primary endpoint: Progression-free survival (PFS) in patients with Met-positive tumors
Endpoint domain: Mortality/survival
Primary endpoint: Change in Score on the Barry-Albright Dystonia (BAD) Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Score on Unified Parkinson's Disease Rating (UPDRS) Scale, Part I-III, VI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Score on Pediatric Quality of Life (PedsQL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percent Change in SALT Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Terminal phase half-life of Recombinant Antihemophilic Factor (rAHF-PFM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of colon ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Disease progression of ITP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients Clear or Minimal Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of Apparent Diffusion Coefficient (ADC) change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of FLT uptake change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pathological quantification (% viable residual tumor cells)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of children with pathological score in epilepsy scales
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Amount of biventricular pacing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Cocaine-positive Urines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of chest ultrasound in predicting extubation readiness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants with Grade 3 or Higher Nonhematologic Adverse Events (AEs) with Cyclophosphamide
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants with Grade 3 or Higher Nonhematologic Adverse Events (AEs) without Cyclophosphamide
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Mean Arterial Pressure (MAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Overall Summary of Tolerability/Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change from Baseline Depression at 12 months
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from Baseline Anxiety at 12 months
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from Baseline Loneliness at 12 months
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change from Baseline Self-harm Risk at 12 months
Endpoint domain: Adverse events/effects
Primary endpoint: Change from Baseline Service Usage at 12 months
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: First successful central venous catheterization rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change From Baseline in Prostate Size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Active range of motion (AROM) pre-surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Active range of motion (AROM) at 12 months follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of the operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Performance on Monetary Incentive Delay task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Signal detection reward task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of morphine related adverse-event
Endpoint domain: Adverse events/effects